131 related articles for article (PubMed ID: 2447997)
1. The role of prostate specific antigen in the baseline assessment of patients undergoing hormone therapy for advanced prostate cancer.
Emtage LA; Lewis PW; Blackledge GR
Br J Urol; 1987 Dec; 60(6):572-7. PubMed ID: 2447997
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen. Monitoring the response of carcinoma of the prostate to radiotherapy with a new tumor marker.
Dundas GS; Porter AT; Venner PM
Cancer; 1990 Jul; 66(1):45-8. PubMed ID: 1693877
[TBL] [Abstract][Full Text] [Related]
3. Haemostatic changes during hormone manipulation in advanced prostate cancer: a comparison of DES 3 mg/day and goserelin 3.6 mg/month.
Emtage LA; George J; Boughton BJ; Trethowan C; Blackledge GR
Eur J Cancer; 1990 Mar; 26(3):315-9. PubMed ID: 2141488
[TBL] [Abstract][Full Text] [Related]
4. Value of biochemical markers in the management of disseminated prostatic cancer.
Mulders PF; Fernandez del Moral P; Theeuwes AG; Oosterhof GO; van Berkel HT; Debruyne FM
Eur Urol; 1992; 21(1):2-5. PubMed ID: 1376692
[TBL] [Abstract][Full Text] [Related]
5. Phase III randomised study of zoladex versus stilboestrol in the treatment of advanced prostate cancer.
Waymont B; Lynch TH; Dunn JA; Emtage LA; Arkell DG; Wallace DM; Blackledge GR
Br J Urol; 1992 Jun; 69(6):614-20. PubMed ID: 1386272
[TBL] [Abstract][Full Text] [Related]
6. Systematic association of PAP and PSA determinations to bone scintigraphy in prostatic cancer.
Fincker F; Sauvan R; Pasquier J
Am J Clin Oncol; 1988; 11 Suppl 2():S68-70. PubMed ID: 2468277
[TBL] [Abstract][Full Text] [Related]
7. Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer.
Cooper EH; Armitage TG; Robinson MR; Newling DW; Richards BR; Smith PH; Denis L; Sylvester R
Cancer; 1990 Sep; 66(5 Suppl):1025-8. PubMed ID: 1697498
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of PSA, free PSA, PSMA, and total and bone alkaline phosphatase levels compared to bone scans in the management of patients with metastatic prostate cancer.
Murphy GP; Troychak MJ; Cobb OE; Bowes VA; Kenny RJ; Barren RJ; Kenny GM; Ragde H; Holmes EH; Wolfert RL
Prostate; 1997 Oct; 33(2):141-6. PubMed ID: 9316655
[TBL] [Abstract][Full Text] [Related]
9. Interim report of a randomized trial comparing Zoladex 3.6 mg depot with diethylstilbestrol 3 mg/day in advanced prostate cancer. The West Midlands Urology Research Group.
Emtage LA; Trethowan C; Hilton C; Kelly K; Blackledge GR
Am J Clin Oncol; 1988; 11 Suppl 2():S173-5. PubMed ID: 2977273
[TBL] [Abstract][Full Text] [Related]
10. Response to orchiectomy following Zoladex therapy for metastatic prostate carcinoma.
Silver RI; Straus FH; Vogelzang NJ; Kellman H; Chodak GW
Urology; 1991 Jan; 37(1):17-21. PubMed ID: 1702566
[TBL] [Abstract][Full Text] [Related]
11. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma.
Peeling WB
Urology; 1989 May; 33(5 Suppl):45-52. PubMed ID: 2523611
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen as a unique routine test in monitoring therapy for inoperable prostate cancer: comparison with radionuclide bone scan and prostatic acid phosphatase.
Barichello M; Gion M; Bonazza A; Delli Ponti US; Bolgan A; Contemori GP; Barioli P; Capitanio G; Pecori B; Omacini S
Eur Urol; 1995; 27(4):295-300. PubMed ID: 7544735
[TBL] [Abstract][Full Text] [Related]
13. Significance of PSA and PAP in patients with or without prostatic cancer.
Caty A; Gosselin P; Cazin JL; Dehaut JM; Adenis L
Am J Clin Oncol; 1988; 11 Suppl 2():S63-4. PubMed ID: 2468275
[TBL] [Abstract][Full Text] [Related]
14. Tumor markers in prostate cancer.
Cooper EH; Robinson MR; Whelan P; Ferro MA
Cancer; 1992 Jul; 70(1 Suppl):225-9. PubMed ID: 1376192
[TBL] [Abstract][Full Text] [Related]
15. Is prostate-specific antigen the most useful marker for screening in prostate cancer?
Delaere KP; Van Dieijen-Visser MP; Gijzen AH; Brombacher PJ
Am J Clin Oncol; 1988; 11 Suppl 2():S65-7. PubMed ID: 2468276
[TBL] [Abstract][Full Text] [Related]
16. The treatment of metastatic prostatic cancer with the slow release LH-RH analogue Zoladex ICI 118630.
Beacock CJ; Buck AC; Zwinck R; Peeling WB; Rees RW; Turkes A; Walker K; Griffiths K
Br J Urol; 1987 May; 59(5):436-42. PubMed ID: 2954605
[TBL] [Abstract][Full Text] [Related]
17. A phase III open randomized study of Zoladex 3.6 mg depot vs. DES 3 mg per day in untreated advanced prostate cancer: a West Midlands Urological Research Group Study.
Emtage LA; Trethowan C; Kelly K; Arkell D; Wallace DM; Hughes M; Hay A; Blacklock R; Jones M; Rouse A
Prog Clin Biol Res; 1989; 303():47-52. PubMed ID: 2528739
[No Abstract] [Full Text] [Related]
18. A comparative study on the diagnostic value of prostatic acid phosphatase (PAP) and prostatic specific antigen (PSA) in patients with carcinoma of the prostate gland.
van Dieijen-Visser MP; Delaere KP; Gijzen AH; Brombacher PJ
Clin Chim Acta; 1988 May; 174(2):131-40. PubMed ID: 2454767
[TBL] [Abstract][Full Text] [Related]
19. High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate-specific antigen to monitor response.
Ferro MA; Gillatt D; Symes MO; Smith PJ
Urology; 1989 Sep; 34(3):134-8. PubMed ID: 2476882
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of prostate-specific antigen in untreated prostatic carcinoma.
Oosterom R; Bogdanowicz J; Schröder FH
Eur Urol; 1989; 16(4):253-7. PubMed ID: 2475344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]